Treatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer

Küçük Resim Yok

Tarih

2013

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Erişim Hakkı

info:eu-repo/semantics/closedAccess

Özet

Treatment options for patients with non-muscle invasive bladder cancer (NMIBC) refractory to intravesical bacillus Calmette-Guérin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NMIBC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this point radical cystectomy is the standard treatment of choice. If this option is not feasible, intravesical chemotherapy with docetaxel or gemcitabine, the combination of BCG and interferon (INF)-á or device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are some of the candidates for further treatment.

Açıklama

Anahtar Kelimeler

BCG failure, Itravesical therapy, Non-muscle invasive bladder cancer

Kaynak

Archivos Espanoles de Urologia

WoS Q Değeri

Scopus Q Değeri

Q4

Cilt

66

Sayı

9

Künye